Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Curr Oncol
Hlavní autoři: Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Multimed Inc. 2020
Témata:
Practice Guideline
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755440/
https://ncbi.nlm.nih.gov/pubmed/33380864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.7297
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky